Innovation in healthcare: at a sector sweet spot?



​​The healthcare sector is experiencing a rapid pace of innovation, a trend that Andy Acker, Portfolio Manager in the Global Life Sciences Team, says is likely to continue in 2019 to the potential benefit of investors.

What do you think are the key themes likely to shape markets in 2019?

We believe innovation will be a driving force for healthcare stocks in 2019. Over the past two years, the US Food and Drug Administration (FDA) approved more than 90 novel therapies. These products, still early in their launch phase, could drive industry growth for years to come.

Many new therapies represent revolutionary advances in medicine. Immuno-oncology medicines, for one, harness the immune system to target and attack cancer cells, often with impressive results. Exciting advances are being made in gene therapies that address rare and debilitating diseases. The first gene therapy was approved in the US in late 2017, and we expect additional approvals as soon as next year. Advances are also being made in medical devices, where the first integrated continuous glucose monitor for diabetes management recently won FDA approval and positive clinical trial data were presented for mitral valve repair and drug-eluting stents. Finally, a consolidation in services is leading to more integrated healthcare services companies.

Where do you see the most important opportunities and risks within your asset class?

Drug pricing reform in the US remains a concern for the healthcare sector, as President Trump has made lowering consumers’ out-of-pocket drug costs a priority. An e-commerce and cloud computing giant’s acquisition in June of an online pharmacy could also lead to disintermediation of the drug-supply chain. Broadly, we believe reforms that remove inefficiencies and improve patient affordability are good for the system in the long term. As always, we also have to think about the binary nature of drug development. For as many drugs that get regulatory approval, a multitude of others never make it out of clinical trials, leading to volatility.

How have your experiences in 2018 shifted your approach or outlook in 2019?

In our opinion, remaining disciplined on valuation in 2018 was critical to managing downside volatility. During the summer, we saw a high level of investor enthusiasm for early-stage biotechnology companies, even though fundamentals did not always support elevated valuations, in our opinion. When the broad equity market declined in October, many of these stocks had the farthest to fall. Consequently, we remain committed to taking a balanced approach, investing across the healthcare sector’s major subindustries, market capitalisations and geographies.

But overall, our enthusiasm for the sector has never been higher. In addition to companies delivering medical breakthroughs, regulators globally have shown their commitment to quickly bringing treatments to market for patients with high, unmet medical needs. With new drugs and medical devices in the process of launching — and major patent cliffs largely behind us — we believe this is a sweet spot for many areas of the sector.

Which themes have the potential to redirect markets in 2019? Download our one-pager summary to find out


Gene therapy: the insertion of normal DNA into cells with a genetic defect. The normal DNA replaces or alters the functioning of the target cell which is responsible for disease.

Mitral valve repair: cardiac surgery to treat or replace diseased or narrowing mitral valve in the heart.

Drug-eluting stent: a mesh scaffold that can prevent blocked arteries. It is inserted into a diseased artery and releases a drug to prevent cell proliferation and eventual artery blockage.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.

Anything non-factual in nature is an opinion of the author(s), and opinions are meant as an illustration of broader themes, are not an indication of trading intent, and are subject to change at any time due to changes in market or economic conditions. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its us.

Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

Key investment risks to be considered before investing.

  • The Fund may invest in any one or a combination of the following instruments:
    • futures, options and swaps and other financial derivative instruments (“FDI”) for investment purposes, up to 10% of the net asset value ("NAV") of the Fund. Given the leverage effect of FDI, such investments may result in substantial loss (as much as 100% of the NAV of the relevant Fund);
    • debt securities rated below investment grade; and
    • mortgage and asset-backed securities and/or in index/structured securities. These financial instruments may be rated below investment grade.
  • Investing in any one of the above instruments may involve substantial credit/counterparty, market, liquidity, currency, leverage, index, interest and swap risks. If the issuers default, or such securities or their underlying assets, cannot be realised or perform badly, investors’ entire investments may be lost.
  • The Fund's investments involve developing markets. Owing to its potentially higher volatility and risk levels, as well as lower political and economic stability than developed markets, asset values could be affected in various levels.
  • The Fund’s investments may be more concentrated in terms of industry risk than others that diversify across industries and may therefore be subject to higher industry risk than funds with more diversified holdings.
  • The investment decision is yours. If you are in any doubt about the contents of this document, you should seek independent professional financial advice.
  • Investors should not only base on this document alone to make investment decisions and should read the Prospectus including the risk factors for further details.

Specific risks

Risk rating


Important message